International Journal of Science and Research (IJSR)

International Journal of Science and Research (IJSR)
Since Year 2012 | Open Access | Fully Refereed | Peer Reviewed

ISSN: 2319-7064




Downloads: 137

Research Paper | Gynaecology | India | Volume 8 Issue 5, May 2019


Comparing the Outcome of Ullipristal Acetate and Mifepristone in the Medical Management of Uterine Fibroids

Dr. Abraham Faby | Dr Sherly Mathen


Abstract: Introduction: Uterine leiomyomas are widely prevalent and frequently cause menorrhagia. The major therapeutic option today is hysterectomy. Medical options are of highest interest. Aim & Objectives: Efficacy and safety of mifepristone in medical management of myoma and to compare two doses - 10 vs.25 mg/day versus ullipristal acetate 5mg/day. Materials & Methods: study period from January 2016 to january 2018. A total of 150 women with uterine leiomyomas randomized to receive 10mg, 25 mg mifepristone Group 1: Patients were randomized and were given oral mifepristone as 25 mg/day in group 1 for 3 months Group 2: oral mifepristone 10 mg/day in group 2 for 3 months. GROUP 3: Patient s were randomized and given ulliprisstal acetate 5mg/day for 3 months All Patients were followed at 1, 3 and 6 months. Haemogram, liver function test, ultrasound with doppler and endometrial histology was performed. . Uterine blood flow and leiomyoma volume were evaluated Endometrial biopsies were obtained prior to and at end of treatment. Relevant biochemistry, symptoms and bleeding were recorded. Primary outcome was reduction in uterine leiomyoma size. Results: There was a significant decrease in the total leiomyoma volume in the mifepristone-treated group, Mifepristone treatment significantly reduced the bleeding days and increased serum haemoglobin values. Serum cortisol levels remained unchanged, while a mild increase in serum androgens was noted. Endometrial biopsies showed no premalignant changes or changes in mitotic indices.1. Comparing the fibroid size in volume between three groups ANOVA test results in a statistically significant difference between the three groups with P-value less than 0.05. Post-hoc tests confirm that there is statistically significant difference between i. Group 1 & Group 2; An average reduction of fibroid size by 51 % more in Group 1 as compared to Group 2 ii. Group 1 & Group 3; An average reduction of fibroid size by 74 % more in Group 1 as compared to Group 3 Patients on ullipristal acetate showed minimal reduction of fibroid with menorrhagia or spotting during the treatment with 10 patients with deranged liver function test. Conclusion: Mifepristone offers an effective treatment option for women with uterine leiomyoma and the associated pronounced uterovaginal bleeding.


Keywords: Ullipristal Acetate, Mifepristone, Fibroids


Edition: Volume 8 Issue 5, May 2019,


Pages: 1520 - 1524


How to Cite this Article?

Dr. Abraham Faby, Dr Sherly Mathen, "Comparing the Outcome of Ullipristal Acetate and Mifepristone in the Medical Management of Uterine Fibroids", International Journal of Science and Research (IJSR), Volume 8 Issue 5, May 2019, pp. 1520-1524, https://www.ijsr.net/get_abstract.php?paper_id=ART20198008

How to Share this Article?

Enter Your Email Address




Similar Articles with Keyword 'Mifepristone'

Downloads: 119

Research Paper, Gynaecology, India, Volume 8 Issue 6, June 2019

Pages: 2164 - 2164

Role of Mifepristone and Misoprostol in Termination of Pregnancies up to 63 Days of Gestation

Dr. Vinita Sahay [2]

Share this Article

Downloads: 120

Research Paper, Gynaecology, India, Volume 8 Issue 10, October 2019

Pages: 1802 - 1804

A Study on Use of Two Doses of Mifepristone Followed by Misoprostol in Pregnancies with Intrauterine Foetal Death in Mid and Late Trimester

B. S. Jodha [4] | Kamlesh Kumar Rawal

Share this Article


Top